Clinical Trial Update: Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating pegaptanib (Macugen) to prevent worsening of cystoid macular edema after cataract surgery in diabetic patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystoid Macular Edema

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Johns Hopkins University | Conditions: Cystoid Macular Edema | Phase 1, Phase 2 | Status: TERMINATED